The Prevalence and Management of Diabetic Nephropathy in Asia

Abstract

Background: Diabetic nephropathy (DN), especially type 2 diabetes, is now increasing rapidly worldwide, also in Asian countries, and is one of the major long-term vascular complications. The pathogenesis of DN involves both genetic and environmental factors. Around 30-40% of type 2 diabetic patients develop DN despite strict blood glucose and/or blood pressure control. Although it is considered that the genetic background may influence the initiation and progression of DN, the candidate genes are still obscure. Summary: To search for genes that are involved in the susceptibility of DN, a candidate gene approach was taken in the beginning before the development of genome-wide association studies. Although a candidate gene approach can detect rare genetic variants, in advance we need known or presumed pathophysiological knowledge of the specific gene. Investigations using spontaneous animal models are important to determine the pathogenesis and treatment of DN patients. There are many spontaneous animal models, such as the NOD and Akita mice for type 1 diabetes and the Ob/Ob, db/db, Tsumura Suzuki Obese Diabetics, and KK-A^y mice for type 2 diabetes. Furthermore, the toxicity of persistent hyperglycemia, the activation of reactive oxygen species, systemic and/or glomerular hypertension, microinflammation, dyslipidemia, and other factors are considered to play important roles. Diabetic patients with normoalbuminuria and normal renal function showed typical histological patterns of DN. The discovery of a specific and reliable diagnostic and prognostic biomarker other than albuminuria is urgently needed and indispensable. Since large clinical trials of oral hypoglycemic drugs in renal failure are lacking, these recommendations will need to be regularly updated after results of larger randomized trials with longer follow-up durations are available. Key Messages: It is necessary to summarize the basic and clinical features of DN patients in Asia and to use these for the treatment of such patients. Facts from East and West: The prevalence of DN is increasing in Asia and Western countries alike. The deletion (D) allele of the angiotensin-converting enzyme gene is associated with progression to end-stage renal disease in Asian patients with DN, but this association is uncertain in Europeans. An association between DN and polymorphism of the gene coding for acetyl coenzyme A carboxylase β has been reported in Asian and Western populations. Both in Japan and the US, criteria for diagnosis are a 5-year history of diabetes and persistent albuminuria. Renal biopsy should be done in patients with severe hematuria, cellular casts and - in the US - hepatitis and HIV to rule out other pathologies. Diabetic retinopathy is considered a key criterion in Japan, but the absence of it does not rule out DN in the US. Enlargement of the kidney is observed as a diagnostic criterion in Japan. The differential use of renal biopsy as diagnostic tool might account for a different prevalence between Asian countries. Some Japanese diabe...

Dorzagliatin (HMS5552), a novel dual‐acting glucokinase activator, improves glycaemic control and pancreatic β‐cell function in patients with type 2 diabetes: A 28‐day treatment study using biomarker‐guided patient selection

“…In addition, the low renal clearance will be an advantage, implying that dorzagliatin can become a new treatment option for T2D patients with impaired renal function. In fact, up to 40% of T2D patients may suffer from renal impairment …”

Concept of Diabetic Kidney Disease - Paradigm Shift from Albuminuria-Based to GFR-Based Kidney Disease -

“…However, the interpretation of albuminuria can be complicated by a number of factors. This is because albuminuria may be increased by other types of progressive kidney disease, episodic hyperglycemia, high blood pressure, high protein diet, exercise, urinary tract infection, fever, and congestive heart failure, and therefore the presence of albuminuria is not always specific to identifying patients with diabetic nephropathy 2) .…”

A low‐cost laboratory‐based method for predicting newly diagnosed biopsy‐proven diabetic nephropathy in people with type 2 diabetes

“…In people with type 2 diabetes in the UK Prospective Diabetes Study, the annual incidence of clinically diagnosed diabetic nephropathy was 2.0%, with a prevalence of 25% 10 years after diagnosis [3]. Diabetic nephropathy is more common in Asian populations [4]. Diabetic nephropathy is estimated to have doubled in the 1990s as an indication for initiating renal replacement therapy [5].…”